MOG and experimental autoimmune encephalomyelitis: We previously carried out the intraperitoneal (i.p.)transfer of genetically modified ES-DCs to protect against myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).